Kojin is harnessing groundbreaking discoveries in cell state and ferroptosis biology to create novel therapies and cures for diseases traditionally considered intractable. By connecting complex cell states to known biochemical processes, Kojin has developed a proprietary approach to ferroptosis-based drug discovery that enables development of selective therapies for a broad range of debilitating diseases.
Kojin is founded by leading scientists Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $60M
Founded date: 2019
Investors 3
| Date | Name | Website |
| 09.06.2021 | Cathay Cap... | cathaycapi... |
| - | Cathay Hea... | health.cat... |
| - | Newpath Ma... | newpath.pa... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.06.2021 | Series A | $60M | - |
Mentions in press and media 1
| Date | Title | Description | Source |
| 09.06.2021 | Kojin Therapeutics Launches with $60 Million Series A to Dev... | Kojin Therapeutics Inc., the leading company developing new targeted therapeutics based on cell stat... | marketscre... |